ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "lupus nephritis and systemic lupus erythematosus (SLE)"

  • Abstract Number: 2044 • 2019 ACR/ARP Annual Meeting

    Expression of SLAMF6 and Its Functional Significance in Podocytes of Lupus Nephritis: Report with Consideration Based on the Results of Microarray Analysis in Podocytes of MRL/lpr Mice

    Takashi Igawa1, Kunihiro Ichinose 1, Ayaka Umetsu 2, Kazusato Hara 3, Shin-ya Nishihata 1, Momoko Okamoto 1, Yushiro Endo 1, Sosuke Tsuji 1, Yoshika Tsuji 1, Ayuko Takatani 1, Toshimasa Shimizu 1, Remi Sumiyoshi 1, Tomohiro Koga 1, Shin-ya Kawashiri 1, Naoki Iwamoto 1, Mami Tamai 1, Hideki Nakamura 1, Tomoki Origuchi 4, George Tsokos 5 and Atsushi Kawakami 6, 1Nagasaki University Graduate School of Biomedical Sciences, Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki, Japan, 2Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, Nagasaki city, Japan, 3Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, Nagasaki, Japan, 4Nagasaki University School of health sciences, Division of physical therapy, Nagasaki, Japan, 5Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, 6Nagasaki University Graduate School of Biomedical Sciences, Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki

    Background/Purpose: Lupus nephritis (LN) is one of the most serious complication of SLE. The alteration of the structural protein in podocytes is known as a mechanism…
  • Abstract Number: 137 • 2018 ACR/ARHP Annual Meeting

    Autoantibody-Inducing CD4 T (aiCD4 T) Cells Which Induce Systemic Lupus Erythematosus (SLE) Contain Follicular Helper T Cell in Addition to the Major IL-21-Producing CXCR5-ICOShiPD1hi Population: Self-Organized Criticality Theory As the Cause of SLE

    Ken Tsumiyama and Shunichi Shiozawa, Institute for Rheumatic Diseases, Nagahama, Japan

    Background/Purpose: We have shown that repeated immunization with antigen induces systemic lupus erythematosus (SLE) in the mice otherwise not prone to spontaneous autoimmune diseases. We…
  • Abstract Number: 272 • 2018 ACR/ARHP Annual Meeting

    Ethnic Disparities in Lupus Nephritis Outcomes in the Inland Empire: Findings from the Southern California Lupus Registry

    Kristal Choi1, Arezoo Haghshenas2, Abigail Benitez3, Lorena Salto1, Karina Torralba4 and Vaneet K. Sandhu2, 1Loma Linda University, Loma Linda, CA, 2Division of Rheumatology, Loma Linda University, Loma Linda, CA, 3Rheumatology, Loma Linda University, Loma Linda, CA, 4Loma Linda University Medical Center, Loma Linda, CA

    Background/Purpose: Loma Linda University Health (LLUH) serves Riverside and San Bernardino County, which are the two largest counties by geographic size in California and make…
  • Abstract Number: 462 • 2018 ACR/ARHP Annual Meeting

    Steroid Use in Pediatric Proliferative Lupus Nephritis

    Nathalie Chalhoub1, Jianghong Deng2, Natasha M. Ruth3, Stacy P. Ardoin4, Mileka Gilbert5, Theresa Hennard6, Linda Hiraki7, Paul T. Jensen8, Andrea M. Knight9, Rebecca Kunder10, Laura Lewandowski11, Siok Hoon Lily Lim12, Angela Merritt13, Sonia Iqbal Savani14, Mary Beth Son15, Emily von Scheven16, Scott E. Wenderfer17 and Hermine I. Brunner6, 1Division of Immunology, Allergy, and Rheumatology, University of Cincinnati College of Medicine, Cincinnati, OH, 2Division of Rheumatology, Beijing Children’s Hospital and Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 3Rheumatology, Medical University of South Carolina, Charleston, SC, 4Division of Rheumatology, Nationwide Children’s Hospital, Columbus, OH, 5Pediatric Rheumatology, Medical University of South Carolina, Charleston, SC, 6Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 7Child Health Evaluative Sciences, The Hospital for Sick Children, Toronto, ON, Canada, 8Internal Medicine, The Ohio State University Wexner Medical Center, Columbus, OH, 9Division of Pediatric Rheumatology, Children's Hospital of Philadelphia, Philadelphia, PA, 10Gilead Sciences, Inc, Redwood City, CA, 11NIAMS/NIH, Bethesda, MD, 12Children's Hospital Research Institute of Manitoba, University of Manitoba, Winnipeg, MB, Canada, 13Pediatric Rheumatology, Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 14Medical University of South Carolina, Charleston, SC, 15Boston Children's Hospital, Harvard Medical School, Brookline, MA, 16Pediatric Rheumatology, University of California San Francisco, San Francisco, CA, 17Pediatrics-Renal, Baylor College of Medicine, Houston, TX

    Background/Purpose: Corticosteroids (CS) are the mainstay of childhood-onset lupus (cSLE) and proliferative lupus nephritis (LN) therapy. However, there are no widely accepted CS dosing regimens…
  • Abstract Number: 726 • 2018 ACR/ARHP Annual Meeting

    Anti-Retinoblastoma Protein Antibody Is Protective Against Lupus Nephritis

    Jessica Li1, Andreas Goules2, Daniel Goldman1, Antony Rosen3, Livia Casciola-Rosen4 and Michelle Petri1, 1Medicine (Rheumatology), Johns Hopkins University School of Medicine, Baltimore, MD, 2Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, 3Division of Rheumatology, The Johns Hopkins University School of Medicine, Baltimore, MD, 4Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD

    Background/Purpose: Retinoblastoma protein (RB) regulates nucleosome/chromatin structures and is linked to tumor suppression. It regulates the cell cycle by repression of E2F transcription factor and…
  • Abstract Number: 736 • 2018 ACR/ARHP Annual Meeting

    Herpes Zoster and Disseminated Zoster in Systemic Lupus Erythematosus and Lupus Nephritis: Incidence Rates in Real-World Claims Data

    Katherine Belendiuk1, Yingjie Ding2, Devika Chawla1 and Matthew Cascino1, 1Genentech, Inc., South San Francisco, CA, 2Genesis Research, Hoboken, NJ

    Background/Purpose: Disseminated zoster is a highly morbid complication of varicella zoster reactivation (herpes zoster) that is typically associated with immunosuppression. Systemic lupus erythematosus (SLE) and…
  • Abstract Number: 757 • 2018 ACR/ARHP Annual Meeting

    Urinary Galectin-3 Binding Protein As a Novel Biomarker of Renal Disease Activity in Lupus Nephritis

    Huihua Ding1, Cheng Ling2, Roberto Bassi3, Shinji L Okitsu4, Julie A. DeMartino4 and Nan Shen1, 1Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China, 2Department of Rheumatology, Renji Hospital, Shanghai JiaoTong University School of Medicine, Shanghai, China, 3EMD Serono Research & Development Institute, Inc. (a business of Merck KGaA, Darmstadt, Germany), Billerica, MA, 4TIP Immunology, EMD Serono Research and Development Institute, Inc., Billerica, MA

    Background/Purpose: Lupus nephritis (LN) is one of the most common and severe manifestations of systemic lupus erythematosus (SLE). This study investigates urinary galecting-3 binding protein…
  • Abstract Number: 776 • 2018 ACR/ARHP Annual Meeting

    MMP7 and CXCL12: Two Promising Biomarkers in Lupus Nephritis

    Sylvie Goletti1,2, Séverine Nieuwland3, Frédéric A. Houssiau2,3 and Bernard R. Lauwerys2,3, 1Service de Microbiologie, Cliniques Universitaires Saint-Luc, Brussels, Belgium, 2Pôle de pathologies rhumatismales systémiques et inflammatoires, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain, Brussels, Belgium, 3Rheumatology Department, Cliniques universitaires Saint-Luc, Brussels, Belgium

    Background/Purpose: Lupus nephritis (LN) is one of the most serious complications of Systemic lupus erythematosus (SLE). Early diagnosis of renal impairment, combined with a strict…
  • Abstract Number: 2121 • 2018 ACR/ARHP Annual Meeting

    Serum High Type I Interferon Is Associated with Active Proliferative Lupus Nephritis in Lupus Patients Accompanied with High Interferon Signature Gene Expression and Plasmacytoid Dendritic Cell Infiltration in Lupus Nephritis Kidney

    Taro Iwamoto1, Jessica M. Dorschner2, Mark A. Jensen1, Shanmugapriya Selvaraj3, Danielle Vsetecka2, Shreyasee Amin2, Ashima Makol2, Floranne C. Ernste2, Thomas Osborn2, Kevin Moder2, Vaidehi R. Chowdhary2, Valeria Mezzano4, Peter M. Izmirly5, H. Michael Belmont5, Robert M. Clancy1, Jill P. Buyon1, Ming Wu3, Cynthia A. Loomis3 and Timothy B. Niewold1, 1Colton Center for Autoimmunity, New York University, New York, NY, 2Mayo Clinic College of Medicine, Rochester, MN, 3Department of Pathology, New York University, New York, NY, 4Division of Cardiology, New York University, New York, NY, 5Division of Rheumatology, New York University, New York, NY

    Background/Purpose: Despite recent advancements in immunosuppressive therapies, lupus nephritis (LN) remains one of the most severe organ manifestations in systemic lupus erythematosus (SLE). High type…
  • Abstract Number: 2127 • 2018 ACR/ARHP Annual Meeting

    A Role of Vascular Cell Adhesion Molecule 1 and Activated Leukocyte Cell Adhesion Molecule in Lupus Nephritis

    Ioannis Parodis1,2, Sirisha Gokaraju3, Agneta Zickert1,2, Ting Zhang3, Deena Habazi3, Anders Larsson4, Elisabet Svenungsson1,2, Chandra Mohan3 and Iva Gunnarsson1,2, 1Division of Rheumatology, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, Stockholm, Sweden, 2Rheumatology, Karolinska University Hospital, Stockholm, Sweden, Stockholm, Sweden, 3Department of Biomedical Engineering, University of Houston, Houston, Texas, USA, Houston, TX, 4Department of Medical Sciences/Clinical Chemistry, Uppsala University, Uppsala, Sweden, Uppsala, Sweden

    Background/Purpose: Reliable non-invasive biomarkers for lupus nephritis (LN) are lacking. We investigated two adhesion molecules as urinary biomarkers in LN, i.e. vascular cell adhesion molecule…
  • Abstract Number: 2641 • 2018 ACR/ARHP Annual Meeting

    Hydroxychloroquine Could Modulate S100 Proteins Expression, Which Reflect the Activity of Lupus Nephritis or Skin Lesion, in Systemic Lupus Erythematosus Patients with Low Disease Activity

    Risa Wakiya, Tomohiro Kameda, Shusaku Nakashima, Hiromi Shimada, Mikiya Kato, Taichi Miyagi, Kiyo Ueeda and Hiroaki Dobashi, Internal Medicine Division of Hematology, Rheumatology, and Respiratory Medicine, Kagawa University, Kagawa, Japan

    Background/Purpose: To find the effect of HCQ treatment on expression of S100 proteins which were reported to reflect the activity of SLE including lupus nephritis…
  • Abstract Number: 2686 • 2018 ACR/ARHP Annual Meeting

    Podocyte Foot Process Width Is a Prediction Marker for Complete Renal Remission at 6 and 12 Months after Induction Therapy in Lupus Nephritis

    Kunihiro Ichinose1, Mineaki Kitamura2, Shuntaro Sato3, Keita Fujikawa4, Yoshiro Horai5, Naoki Matsuoka6, Masahiko Tsuboi6, Fumiaki Nonaka7, Masataka Umeda1, Tomohiro Koga8, Takashi Igawa8, Tomoya Nishino2 and Atsushi Kawakami8, 1Department of Immunology and Rheumatology, Unit of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, 2Department of Nephrology, Nagasaki University Hospital, Nagasaki, Japan, 3Clinical Research Center, Nagasaki University Hospital, Nagasaki, Japan, 4Japan Community Health care Organization Isahaya General Hospital, Nagasaki, Japan, 5Department of Rheumatology, Clinical Research Center, NHO Nagasaki Medical Center, Omura, Japan, 6Nagasaki Medical Hospital of Rheumatology, Nagasaki, Japan, 7Department of Internal Medicine, Sasebo City General Hospital, Sasebo, Japan, 8Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan

    Background/Purpose: Lupus nephritis (LN) is a most important predictor of morbidity and mortality in patients with systemic lupus erythematosus (SLE).Histopathology samples from patients with LN…
  • Abstract Number: 2620 • 2017 ACR/ARHP Annual Meeting

    The Value of Repeat Biopsy in the Management of Lupus Nephritis Flares

    Javier Narváez1,2, Milagros Ricse2, Montserrat Goma3, Francesca Mitjavila4, Xavier Fulladosa5, Olga Capdevila4, Joan Torras5, Xavier Juanola2,6, Ramon Pujol4 and Joan Miquel Nolla2, 1Rheumatology Department, Hospital de Bellvitge. Barcelona. Spain, L’Hospitalet de Llobregat, Spain, 2Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain, 3Pathology, Hospital Universitario de Bellvitge, Barcelona, Spain, 4Internal Medicine, Hospital Universitario de Bellvitge, Barcelona, Spain, 5Nephrology, Hospital Universitario de Bellvitge, Barcelona, Spain, 6Rheumatology, University Hospital Bellvitge, Barcelona, Spain

    Background/Purpose: Whether a repeat renal biopsy is helpful during lupus nephritis (LN) flares remains debatable. Our objective was to analyze the clinical utility of repeat…
  • Abstract Number: 2922 • 2017 ACR/ARHP Annual Meeting

    Outcomes of Lupus Nephritis in Vulnerable Populations

    Christine Peschken1, Rebecca Gole2, Carol A Hitchon3, David Robinson3, Ada Man4, Annaliese Tisseverasinghe4 and Hani El-Gabalawy4, 1Medicine & Community Health Sciences, University of Manitoba, Winnipeg, MB, Canada, 2University of Manitoba, Winnipeg, MB, Canada, 3Arthritis Center, University of Manitoba, Winnipeg, MB, Canada, 4Rheumatology, University of Manitoba, Winnipeg, MB, Canada

    Background/Purpose: Lupus nephritis is a known predictor of mortality; we have previously shown an increased frequency of nephritis in North American Indian (NAI) and Asian…
  • Abstract Number: 663 • 2017 ACR/ARHP Annual Meeting

    Urinary Tumor-Necrosis Factor-like Weak Inducer of Apoptosis Is an Important Biomarker for Renal Lupus

    Michelle Petri1, Daniel Goldman2, Linda Burkly3, Nicolas Wisniacki4, Chris Stebbins3 and Laurence S Magder5, 1Medicine (Rheumatology), Division of Rheumatology, Johns Hopkins University School of Medicine, MD, USA, Baltimore, MD, 2Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, 3Biogen, Cambridge, MA, 4GlaxoSmithKline, London, United Kingdom, 5Epidemiology and Public health, University of Maryland School of Medicine, Baltimore, MD

    Background/Purpose: Tumor-necrosis factor (TNF)-like weak inducer of apoptosis (TWEAK) drives release of proinflammatory mediators from renal tubular and mesangial cells, and has been implicated in…
  • 1
  • 2
  • 3
  • 4
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology